BiotechTube
Yamo Pharmaceuticals

Yamo Pharmaceuticals

San Diego, United States· Est.
yamopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $45M

Overview

Yamo Pharmaceuticals is a private, pre-revenue biotech company founded in 2017, advancing L1-79 for Autism Spectrum Disorder (ASD). The therapy, which regulates catecholamine pathways in the central and autonomic nervous systems, recently concluded a Phase 2 study in July 2024, showing promising efficacy and a well-tolerated profile. The company is positioned to address a large, underserved market with no approved pharmacologic treatments for the core social symptoms of ASD. Success in future clinical development could establish Yamo as a leader in neurodevelopmental therapeutics.

NeurologyPsychiatry

Technology Platform

Small molecule platform targeting the regulation of catecholamine networks in the central and autonomic nervous systems to address core deficits in social behavior and communication.

Funding History

2
Total raised:$45M
Series B$30M
Series A$15M

Opportunities

The primary opportunity is addressing the massive, completely unmet need for a pharmacologic treatment targeting the core social symptoms of Autism Spectrum Disorder (ASD).
Success with L1-79 could establish a new treatment paradigm and capture a multi-billion dollar global market.
Positive Phase 2 data also creates opportunities for strategic partnerships or acquisition by a larger pharma company.

Risk Factors

The company faces high clinical risk as its single asset, L1-79, must succeed in larger, costly Phase 3 trials.
Regulatory risk is significant due to the novel endpoint of treating ASD core symptoms.
As a pre-revenue, private company, it also carries substantial financing risk to fund development through to approval.

Competitive Landscape

The competitive landscape for ASD core symptoms is nascent but growing. While no drugs are approved for this indication, several biopharma companies are investigating various mechanisms. Yamo's differentiation lies in its specific focus on catecholamine modulation. Current competition primarily consists of generic drugs used off-label for associated symptoms, not direct competitors for L1-79's proposed mechanism.

More companies in Small Molecule Drugs →More companies in United States →